Disease · MONDO_0005689

cannabis dependence

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cannabis dependence. Diseases, record MONDO_0005689. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005689

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cannabis dependence; Open Targets
Open Targets ID: MONDO_0005689; Open Targets
Other names: Cannabis-Related Disorder, Hashish Abuse, Marihuana Abuse, cannabis abuse, marijuana dependence; Open Targets
Disease Ontology: DOID:1849; Disease Ontology
Disease Ontology: DOID:9505; Disease Ontology
MeSH: D002189; MeSH
NCI Thesaurus: C34445; NCI Thesaurus
Highest stage of its drugs: Phase 2/3, for 5 of its 32 drugs, from ClinicalTrials.gov; Open Targets

Drugs32

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DRONABINOL	CHEMBL465	Small molecule	Phase 2/3	ClinicalTrials.gov	7	7	7	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	3	Drugs and targets
CLONIDINE	CHEMBL134	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LOFEXIDINE	CHEMBL17860	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
NABILONE	CHEMBL2218896	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ATOMOXETINE	CHEMBL641	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
APREPITANT	CHEMBL1471	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 32

See all 32 drugs

Targets71

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor alpha-2	3	Adrenergic receptor alpha-2 agonist	Phase 2/3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	3	Adrenergic receptor alpha-2 agonist	Phase 2/3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	3	Adrenergic receptor alpha-2 agonist	Phase 2/3	https://conductscience.org/library/genes/152	Drugs and targets
CNR1	Cannabinoid receptor 1	3	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/1268	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	3	Serotonin 2c (5-HT2c) receptor agonist; Serotonin 2c (5-HT2c) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3358	Drugs and targets
CACNA1A	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1C	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1E	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 2	https://conductscience.org/library/genes/777	Drugs and targets

1 to 10 of 71

See all 71 targets

Trials51

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01964404	Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?	Phase 1	263	2025-12-09	Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder	DRONABINOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT03055377	N-Acetylcysteine for Youth Cannabis Use Disorder	Phase 2/3	192	2024-12-17	Cannabis Use Disorder	ACETYLCYSTEINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03980561	UH3 Varenicline for Cannabis Use Disorder	Phase 2	174	2024-01-18	Cannabis Use Disorder	VARENICLINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01020019	Combined Pharmacotherapy for Cannabis Dependency	Phase 2/3	156	2016-05-11	Cannabis Dependence, Marijuana Dependence	DRONABINOL, LOFEXIDINE	Its record names the disease	ClinicalTrials.gov
NCT00974376	Gabapentin Treatment of Cannabis Dependence	Phase 2	150	2017-06-06	Cannabis Dependence, Cannabis Withdrawal, Cognitive Deficits	GABAPENTIN	Its record names the disease	ClinicalTrials.gov
NCT03729869	Impact of Progesterone on Stress Reactivity and Cannabis Use	Phase 2	148	2023-09-28	Cannabis Use	PROGESTERONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01697709	Quetiapine Pharmacotherapy for Cannabis Dependence	Phase 2	130	2019-02-05	Cannabis Dependence	QUETIAPINE	Its record names the disease	ClinicalTrials.gov
NCT01005810	A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana	Phase 2	116	2018-11-21	Cannabis Dependence	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT01347762	Nabilone for Cannabis Dependence: A Pilot Study	Phase 2/3	84	2018-06-01	Cannabis Dependence, Marijuana Dependence	NABILONE	Its record names the disease	ClinicalTrials.gov
NCT01574183	Vilazodone Treatment for Marijuana Dependence	Phase 2	76	2016-01-14	Marijuana Dependence	VILAZODONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 51

See all 51 trials

Comparisons in its trials41

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Gabapentin 1200mg/Day vs Placebo: serious adverse events	0 of 150	1 of 150	300	NCT00974376	Trial comparisons
N-acetylcysteine vs Placebo: deaths from any cause	0 of 98	0 of 94	192	NCT03055377	Trial comparisons
N-acetylcysteine vs Placebo: serious adverse events	0 of 98	0 of 94	192	NCT03055377	Trial comparisons
Varenicline vs Placebo: deaths from any cause	0 of 90	0 of 84	174	NCT03980561	Trial comparisons
Varenicline vs Placebo: serious adverse events	1 of 90	0 of 84	174	NCT03980561	Trial comparisons
Quetiapine vs Placebo: deaths from any cause	0 of 66	0 of 64	130	NCT01697709	Trial comparisons
Quetiapine vs Placebo: serious adverse events	0 of 66	0 of 64	130	NCT01697709	Trial comparisons
Lofexidine and Dronabinol vs Placebo: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback.	17 of 61	18 of 61	122	NCT01020019	Trial comparisons
Lofexidine and Dronabinol vs Placebo: serious adverse events	1 of 61	1 of 61	122	NCT01020019	Trial comparisons
N-Acetylcysteine vs Placebo: deaths from any cause	0 of 58	0 of 58	116	NCT01005810	Trial comparisons

1 to 10 of 41

See all 41 comparisons in its trials

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22373942	RESULT	1	PubMed
20576364	RESULT	1	PubMed
18182254	RESULT	1	PubMed
16223067	RESULT	1	PubMed
39910268	DERIVED	1	PubMed
39021751	DERIVED	1	PubMed
37692969	DERIVED	1	PubMed
36598543	DERIVED	1	PubMed
34390300	DERIVED	1	PubMed
32735782	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005689

GET https://conductscience.org/api/diseases/v1/MONDO_0005689/drugs?page=2

API reference For AI assistants